Q1 2020 · —
Revenue—
Net Income-$6.40M-$6.40M N/M vs Q1 2019N/M vs Q4 2019
EPS Diluted-$0.90-$0.90 no prior Q1 2019 on fileno prior Q4 2019 on file
Operating Income-$5,831,000N/M
Operating Cash Flow-$7,761,000N/M
Free Cash Flowderived-$7,773,000—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2020 | Q1 2019 |
|---|---|---|
| Net Income | -$6.40M | -$10.77M |
| EPS Diluted | -$0.90 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR